Author:
Li Yan-Ping,Liang Zheng-Lun,Xia Jie-Lai,Wu Jun-Yu,Wang Ling,Song Li-Fei,Mao Qun-Ying,Wen Shu-Qun,Huang Ren-Guo,Hu Yuan-Sheng,Yao Xin,Miao Xu,Wu Xing,Li Rong-Cheng,Wang Jun-Zhi,Yin Wei-Dong
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Immunology and Allergy
Reference35 articles.
1. Basic rationale, current methods and future directions for molecular typing of human enterovirus;Nasri;Expert Rev Mol Diagn,2007
2. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group;Ho;N Engl J Med,1999
3. Identification of enterovirus 71 isolates from an outbreak of hand, foot and mouth disease (HFMD) with fatal cases of encephalomyelitis in Malaysia;AbuBakar;Virus Res,1999
4. Deaths in children during an outbreak of hand, foot and mouth disease in Peninsular Malaysia–clinical and pathological characteristics;Shekhar;Med J Malaysia,2005
5. Outbreak of enterovirus 71 infection in Victoria, Australia, with a high incidence of neurologic involvement;Gilbert;Pediatr Infect Dis J,1988
Cited by
43 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Factors related to the mortality risk of severe hand, foot, and mouth diseases (HFMD): a 5-year hospital-based survey in Guangxi, Southern China;BMC Infectious Diseases;2023-03-08
2. Immunogenicity and Safety of an Inactivated Enterovirus 71 Vaccine Administered Simultaneously with Hepatitis B Virus Vaccine, Group A Meningococcal Polysaccharide Vaccine, Measles-Rubella Combined Vaccine and Japanese Encephalitis Vaccine: A Multi-Center, Randomized, Controlled Clinical Trial in China;Vaccines;2022-06-02
3. Relationship between meteorological factors, air pollutants and hand, foot and mouth disease from 2014 to 2020;BMC Public Health;2022-05-17
4. Progress in Novel Vaccine Clinical Epidemiology Research in China;Progress in China Epidemiology;2022
5. Immunogenicity and safety of an inactivated enterovirus 71 vaccine co-administered with measles-mumps-rubella vaccine and live-attenuated Japanese encephalitis vaccine: a phase 4, single-center, randomized controlled trial;Human Vaccines & Immunotherapeutics;2021-12-14